Dr. Anton Grasch, MD
Family Medicine (Family Medicine Physician)
820 N Chelan Ave
Wenatchee, WA 98801
Who else practices at this address →
Chelan County is a federal primary care and dental and mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- Southern Illinois University School of Medicine (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 17
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: Southern Illinois University School of Medicine
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
WA license MD61132306 · IL license 125063529
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Confluence Health Hospital Wenatchee, WA
Medical groups
- Central Washington Health Services Association (721 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 17
- Services billed
- 53
- Patients’ average age
- 68
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 30 payments worth $18,938 in total to this clinician.
| Eli Lilly and Company | $18,938 |
|---|
| Food and Beverage | $10,197 |
|---|---|
| Consulting Fee | $5,600 |
| Travel and Lodging | $3,141 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Feb 4, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,500 |
| Eli Lilly and Company Mar 11, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,400 |
| Eli Lilly and Company Apr 14, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $700 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $525 |
| Eli Lilly and Company Jan 23, 2025 | Travel and Lodging travel to INDIANAPOLIS, IN · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $471 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, WA · in-kind | $328 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, WA · in-kind | $215 |
All 25 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Eli Lilly and Company Apr 14, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $700 |
| Eli Lilly and Company Mar 11, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,400 |
| Eli Lilly and Company Feb 4, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $3,500 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $525 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, WA · in-kind | $328 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $269 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, WA · in-kind | $215 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $90.00 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $51.00 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $46.06 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $46.06 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $45.73 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $6.96 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $3.96 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $3.32 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $1.99 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind | $1.99 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $1.49 |
| Eli Lilly and Company Feb 3, 2025 | Travel and Lodging travel to HOUSTON, TX · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $0.43 |
| Eli Lilly and Company Jan 23, 2025 | Travel and Lodging travel to INDIANAPOLIS, IN · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $471 |
| Eli Lilly and Company Jan 23, 2025 | Travel and Lodging travel to INDIANAPOLIS, IN · in-kind Company’s descriptionGROUND TRANSPORTATION EXPENSES FOR A RESEARCH RELATED MEETING WHICH MAY HAVE LASTED MULTIPLE DAYS | $178 |
| Eli Lilly and Company Jan 23, 2025 | Travel and Lodging travel to INDIANAPOLIS, IN · in-kind | $159 |
| Eli Lilly and Company Jan 23, 2025 | Travel and Lodging travel to INDIANAPOLIS, IN · in-kind | $159 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 5 companies. The companies reported $1,632,306 in research payments for these studies, mostly to the institutions running them.
- A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
ModernaTX, Inc. · Completed · NCT06602024 - A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06683508 - A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT06603571 - Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Eli Lilly and Company · Active, not recruiting · NCT06260722 - A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company · Active, not recruiting · NCT05556512 - Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy
Eli Lilly and Company · Status unknown · NCT02968303 - A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Completed · NCT06230523 - A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company · Recruiting · NCT06143956 - A phase 3 study to evaluate the efficacy immunogenicity and safety of respiratory syncytial virus rsv prefusion f subunit vaccine in adults
Pfizer Inc. - A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.